Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer

Gerold Bepler,Charles C. Williams,Michael J. Schell,Wei Chen,Zhong Zheng,George R. Simon,Shirish M. Gadgeel,Xiuhua Zhao,Fred Schreiber,Julie R. Brahmer,Alberto Chiappori,Tawee Tanvetyanon,Mary Pinder-Schenck,Jhanelle E. Gray,Eric B. Haura,Scott Antonia,Juergen R. Fischer

Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer

2013

Gerold Bepler
Charles C. Williams
Michael J. Schell
Wei Chen
Zhong Zheng
George R. Simon
Shirish M. Gadgeel
Xiuhua Zhao
Fred Schreiber
Julie R. Brahmer
Alberto Chiappori
Tawee Tanvetyanon
Mary Pinder-Schenck
Jhanelle E. Gray
Eric B. Haura
Scott Antonia
Juergen R. Fischer

Purpose We assessed whether chemotherapy selection based on in situ ERCC1 and RRM1 protein levels would improve survival in patients with advanced non‐small-cell lung cancer (NSCLC).

Keywords:

Carboplatin
Cell
ERCC1
Deoxycytidine
Gemcitabine
RRM1 Protein
Lung cancer
Pathology
Oncology
Internal medicine
Chemotherapy
Medicine
non small cell
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

119

Citations